RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: LD201
Target: L-selectin–IgG fusion protein (LS-Rg)
Type of nucleic acid: ssDNA
Sequence: 5'CTACCTACGATCTGACTAGCCAAGGTAACCAGTACAAGGTGCTAAACGTAATGGCTTCGGCTTACTCTCATGTAGTTCC3'
Sequence length: 79
GC content: 0.4683544303797468
Affinity: Kd: 1.8 ± 0.2 nM
Pool type: 5'-CTACCTACGATCTGACTAGC-N40-GCTTACTCTCATGTAGTTCC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Hepes, pH 7.5, 125 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl) plus 0.01% (wt/vol) human serum albumin (Sigma Chemical Co., St. Louis, MO)
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated at both the 5' and 3' ends (ld201t1)
Application as quoted in the referenced paper: Therapeutic: " Aptamers that bind with nanomolar affinity to L-selectin's lectin domain, prevent L-selectin from binding to SLex, and function in vivo to prevent the homing of human lymphocytes to lymph nodes in severe combined immunodeficiency (SCID) mice"
Reference (1996, J Clin Invest ): Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K., Bargatze, R. F., Chang, Y. F., Ringquist, S., Moon-McDermott, L., Jennings, S., Fitzwater, T., Han, H. L., Varki, N., Albinana, I., Willis, M. C., Varki, A., & Parma, D. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. The Journal of clinical investigation, 98(12), 2688–2692. https://doi.org/10.1172/JCI119092
Aptamer: LD196
Target: L-selectin–IgG fusion protein (LS-Rg)
Type of nucleic acid: ssDNA
Sequence: 5'CTACCTACGATCTGACTAGCTGGCGGTACGGGCCGTGCACCCACTTACCTGGGAAGTGAGCTTACTCTCATGTAGTTCC3'
Sequence length: 79
GC content: 0.5569620253164557
Affinity: Kd: 3.1 ± 0.4 nM
Pool type: 5'-CTACCTACGATCTGACTAGC-N40-GCTTACTCTCATGTAGTTCC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Hepes, pH 7.5, 125 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl) plus 0.01% (wt/vol) human serum albumin (Sigma Chemical Co., St. Louis, MO)
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated at both the 5' and 3' ends (ld196t1)
Application as quoted in the referenced paper: Therapeutic: " Aptamers that bind with nanomolar affinity to L-selectin's lectin domain, prevent L-selectin from binding to SLex, and function in vivo to prevent the homing of human lymphocytes to lymph nodes in severe combined immunodeficiency (SCID) mice"
Reference (1996, J Clin Invest ): Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K., Bargatze, R. F., Chang, Y. F., Ringquist, S., Moon-McDermott, L., Jennings, S., Fitzwater, T., Han, H. L., Varki, N., Albinana, I., Willis, M. C., Varki, A., & Parma, D. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. The Journal of clinical investigation, 98(12), 2688–2692. https://doi.org/10.1172/JCI119092
Aptamer: LD201t1
Target: L-selectin–IgG fusion protein (LS-Rg)
Type of nucleic acid: ssDNA
Sequence: 5'TAGCCAAGGTAACCAGTACAAGGTGCTAAACGTAATGGCTTCGGCTTAC3'
Sequence length: 49
GC content: 0.4693877551020408
Affinity: Not reported
Pool type: 5'-CTACCTACGATCTGACTAGC-N40-GCTTACTCTCATGTAGTTCC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Hepes, pH 7.5, 125 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl) plus 0.01% (wt/vol) human serum albumin (Sigma Chemical Co., St. Louis, MO)
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Aptamers that bind with nanomolar affinity to L-selectin's lectin domain, prevent L-selectin from binding to SLex, and function in vivo to prevent the homing of human lymphocytes to lymph nodes in severe combined immunodeficiency (SCID) mice"
Reference (1996, J Clin Invest ): Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K., Bargatze, R. F., Chang, Y. F., Ringquist, S., Moon-McDermott, L., Jennings, S., Fitzwater, T., Han, H. L., Varki, N., Albinana, I., Willis, M. C., Varki, A., & Parma, D. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. The Journal of clinical investigation, 98(12), 2688–2692. https://doi.org/10.1172/JCI119092
Aptamer: LD174t1
Target: L-selectin–IgG fusion protein (LS-Rg)
Type of nucleic acid: ssDNA
Sequence: 5'TAGCCATTCACCATGGCCCCTTCCTACGTATGTTCTGCGGGTGGCTTA3'
Sequence length: 48
GC content: 0.5416666666666666
Affinity: Not reported
Pool type: 5'-CTACCTACGATCTGACTAGC-N40-GCTTACTCTCATGTAGTTCC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Hepes, pH 7.5, 125 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl) plus 0.01% (wt/vol) human serum albumin (Sigma Chemical Co., St. Louis, MO)
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " Aptamers that bind with nanomolar affinity to L-selectin's lectin domain, prevent L-selectin from binding to SLex, and function in vivo to prevent the homing of human lymphocytes to lymph nodes in severe combined immunodeficiency (SCID) mice"
Reference (1996, J Clin Invest ): Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K., Bargatze, R. F., Chang, Y. F., Ringquist, S., Moon-McDermott, L., Jennings, S., Fitzwater, T., Han, H. L., Varki, N., Albinana, I., Willis, M. C., Varki, A., & Parma, D. (1996). DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. The Journal of clinical investigation, 98(12), 2688–2692. https://doi.org/10.1172/JCI119092
Aptamer: DNAA
Target: Isoleucyl-tRNA synthetase (tRNAIle)
Type of nucleic acid: ssDNA
Sequence: 5'CATCGCAAGCTTCCAGAGGGGACGCTGAGGCTTCTATGGTTCCGTAGAATTCCACGCG3'
Sequence length: 58
GC content: 0.5689655172413793
Affinity: Kd: 1.5 uM
Pool type: 5'-CATCGCAAGCTTCCAGAG-N25-CGTAGAATTCCACGCGTG-3'
Pool random region: 25
Binding buffer/conditions: 20 mM Hepes, pH 7.5 / 150 mM NH4Cl / 1 mM MgCl2 / 10 ug of bovine serum albumin per ml / 1 mM 2-mercaptoethanol
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Our results demonstrate that aptamers have useful applications for answering questions in mechanistic enzymology, such as the role of an acceptor hydroxyl group in the editing reaction. Although DNA aptamers have been selected to bind small molecule ligands and specific proteins such as thrombin, the experiments reported here are the first to show that a DNA aptamer can work in concert with an enzyme to produce a catalytic (turnover) event with high substrate specificity."
Additional information: *Pool specifies N25 but the aptamer sequence (excluding the primers) has a 26nt random region. There is an extra nucleotide 
Reference (1996, Proc Natl Acad Sci U S A ): Hale, S. P., & Schimmel, P. (1996). Protein synthesis editing by a DNA aptamer. Proceedings of the National Academy of Sciences of the United States of America, 93(7), 2755–2758. https://doi.org/10.1073/pnas.93.7.2755
Aptamer: 10G-1
Target: NS3 protease of hepatitis C virus (HCV)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAACUCGAUGAAGCGAAUUCUGUUGGCGAACUGUACGCAAGUACACUGGAUGACAGGCCUAUCUAUCGGAUCCACG3'
Sequence length: 78
GC content: 0.5128205128205128
Affinity: Kd: 650 nM
Pool type: 5'-GGGAACUCGAUGAAGCGAAUUCUGU-N6-9-GUACGCAAGUAC-N6-9-ACAGGCCUAUCUAUCGGAUCCACG-3'
Pool random region: 12
Binding buffer/conditions: 50 mM Tris/HCl, pH 7.7, 30 mM NaCl, 5 mM CaCl2, 10 mM dithiothreitol
Divalent salt: CaCl
Buffer type: Tris Buffers
pH: 7.7
Molecular weight of target: 110 kDa
Application as quoted in the referenced paper: Drug Development: "By phosphate-modification-interference analysis we showed that the phosphate residues that are critical for the binding of 10G-1 to NS3 lie within the selected regions of the aptamer and that binding involves electrostatic contacts with the phosphates of regions G28-U34 and A47-A55. The NS3-binding region in 10G-1 can serve as a basis for designing more potential inhibitors of the NS3 protein. Thus, there is a need to design more specific inhibitors for the NS3 protease to develop anti-HCV compounds."
Reference (1997, Eur J Biochem ): Urvil, P. T., Kakiuchi, N., Zhou, D. M., Shimotohno, K., Kumar, P. K., & Nishikawa, S. (1997). Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. European journal of biochemistry, 248(1), 130–138. https://doi.org/10.1111/j.1432-1033.1997.t01-1-00130.x
Aptamer: 30-8
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGATGCCTGTCGAGCATGCTGTGAATAGGTAGGGTCGGATGGGCTACGGTGTAGCTAAACTGCTTTGTCGACGGG3'
Sequence length: 75
GC content: 0.5466666666666666
Affinity: Kd: 0.4 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-14
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGATGCCTGTCGAGCATGCTGTTGTGGTAGGGTTAGGGATGGTAGCGGTTGTAGCTAAACTGCTTTGTCGACGGG3'
Sequence length: 75
GC content: 0.5333333333333333
Affinity: Kd: 0.96 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-16
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGATGCCTGTCGAGCATGCTGTCAGCTACCGTGGTAGGGAAGGTTGGAGTGTAGCTAAACTGCTTTGTCGACGGG3'
Sequence length: 75
GC content: 0.5466666666666666
Affinity: Not reported
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-16[29]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'CTACCGTGGTAGGGAAGGTTGGAGTGTAG3'
Sequence length: 29
GC content: 0.5517241379310345
Affinity: Kd: 30 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-16[27]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'TACCGTGGTAGGGAAGGTTGGAGTGTA3'
Sequence length: 27
GC content: 0.5185185185185185
Affinity: Kd: 126 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-38
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGATGCCTGTCGAGCATGCTAGACCCGTGGTAGGGTAGGATGGGGTGGTCGTAGCTAAACTGCTTTGTCGACGGG3'
Sequence length: 75
GC content: 0.5733333333333334
Affinity: Not reported
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-38[29]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'GACCCGTGGTAGGGTAGGATGGGGTGGTC3'
Sequence length: 29
GC content: 0.6551724137931034
Affinity: Kd: 0.90 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 30-38[27]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'ACCCGTGGTAGGGTAGGATGGGGTGGT3'
Sequence length: 27
GC content: 0.6296296296296297
Affinity: Kd: 42 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N30-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 30
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 60-18
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGATGCCTGTCGAGCATGCTCTTTGGAGACAGTCCGTGGTAGGGCAGGTTGGGGTGACTTCGTGGAAGAAGCGAGACGGTGTAGCTAAACTGCTTTGTCGACGGG3'
Sequence length: 105
GC content: 0.5619047619047619
Affinity: Kd: 0.92 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N60-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 60
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 60-18[38]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'CAGTCCGTGGTAGGGCAGGTTGGGGTGACTTCGTGGAA3'
Sequence length: 38
GC content: 0.6052631578947368
Affinity: Kd: 0.5 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N60-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 60
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 60-18[29]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5′AGTCCGTGGTAGGGCAGGTTGGGGTGACT3′
Sequence length: 29
GC content: 0.6206896551724138
Affinity: Kd: 0.5 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N60-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 60
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Additional information: The 15-nucleotide core sequence has eight highly conserved guanine residues and forms a G-quadruplex structure. A single nucleotide within the G-quadruplex structure can direct the DNA to a distinct epitope.
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: 60-18[27]
Target: Thrombin, Human
Type of nucleic acid: ssDNA
Sequence: 5'GTCCGTGGTAGGGCAGGTTGGGGTGAC3'
Sequence length: 27
GC content: 0.6666666666666666
Affinity: Kd: 0.7 nM
Pool type: 5'-AGATGCCTGTCGAGCATGCT-N60-GTAGCTAAACTGCTTTGTCGACGGG-3'
Pool random region: 60
Binding buffer/conditions: 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl2 at 37°C
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Therapeutic: " The SELEX process has been used to isolate single-stranded DNA ligands to human thrombin. Here, a 29-nucleotide single-stranded DNA ligand to human thrombin, designated 60-18[29], with a Kd of approximately 0.5 nM is described. DNA 60-18[29] inhibits thrombin-catalyzed fibrin clot formation in vitro."
Reference (1997, J Mol Biol ): Tasset, D. M., Kubik, M. F., & Steiner, W. (1997). Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. Journal of molecular biology, 272(5), 688–698. https://doi.org/10.1006/jmbi.1997.1275
Aptamer: dopa2
Target: Dopamine
Type of nucleic acid: ssRNA
Sequence: 5'GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCCAGUCCGUUCGGGAUCCUC3'
Sequence length: 111
GC content: 0.5855855855855856
Affinity: Kd: 2.8 µM
Pool type: 5'-GGGAATTCCGCGTGTGC-N80-GTCCGTTCGGGATCCTC-3'
Pool random region: 80
Binding buffer/conditions: 0.15 M NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, and 0.02% ascorbic acid
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: Not reported 
Post-SELEX modifications: The aptamer was truncated
Application as quoted in the referenced paper: Research: " Selection experiments can provide insights into RNA structure and can also be used to refine existing structures. We suggest that a structure like the one described for the dopamine aptamers could form by long-range interactions in natural RNA molecules."
Reference (1997, Biochemistry ): Mannironi, C., Di Nardo, A., Fruscoloni, P., & Tocchini-Valentini, G. P. (1997). In vitro selection of dopamine RNA ligands. Biochemistry, 36(32), 9726–9734. https://doi.org/10.1021/bi9700633